

Madrid, April 24, 2026

Pursuant to the provisions of Article 228 of Law 6/2023, of March 17, on Securities Markets and Investment Services, and related provisions, as well as Circular 3/2020 on information to be provided by companies listed on the BME Growth segment of BME MTF Equity (the “**BME Growth Circular 3/2020**”), LABIANA HEALTH, S.A. (“LABIANA” or the “Company”) hereby informs you of the following:

### **OTHER RELEVANT INFORMATION**

The Company, in accordance with the provisions of BME Growth Circular 3/2020, as anticipated in the “Other Relevant Information” disclosure published on April 21, 2026, hereby discloses the details and reasons for the qualification contained in the audit report on the consolidated financial statements of LABIANA HEALTH, S.A. and SUBSIDIARIES for the fiscal year ended December 31, 2025, together with the management report, as well as the corresponding actions to address the matter and the expected timeline for doing so:

#### **• Scope and reasons for the qualification**

The qualification included in the audit report relates to the valuation of the Company’s equity interest in the entity **Veterinarski Zavod Subotica**, in which Labiana holds a 10% stake following the dilution transaction carried out in fiscal year 2024, which resulted in its exclusion from the Group’s scope of consolidation.

This investment is recorded as an asset on the Company’s consolidated balance sheet.

As indicated by the external auditor in the “Basis for Qualified Opinion,” it has not been possible to obtain adequate and sufficient evidence to determine the recoverable amount of said investment or to conclude whether the amount at which it is recorded should be adjusted.

This limitation is due to the inability to access the necessary financial information from the investee and/or its auditor in a timely manner, a circumstance beyond the Company’s control, given that Labiana does not exercise control over said entity and holds only a minority interest.

Notwithstanding the foregoing, the external auditor concludes that:

“In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying consolidated financial statements present, in all material respects, a true and fair view of the Group’s net assets and financial position as of December 31, 2025, as well as of its results and cash flows for the year then

ended, in accordance with the applicable financial reporting framework.”

• **Actions Taken by the Company**

During the 2025 fiscal year, the Company has continued to work actively to resolve this situation, in coordination with the external auditor, carrying out, among others, the following actions:

- i. Intensification of contacts with the management of the investee company with the aim of obtaining the necessary financial information.
- ii. Repeated requests for the documentation required by the external auditor to assess the recoverable amount of the asset.
- iii. Exercising its rights as a minority shareholder, within the framework of applicable regulations.
- iv. Continuous coordination with the external auditor to facilitate the collection of sufficient and appropriate evidence.

• **Current situation and outlook**

As of the date of preparation of the annual financial statements for the 2025 fiscal year, the Company has not been able to obtain the necessary information to allow the external auditor to verify the recoverable amount of the aforementioned investment.

Consequently, the qualification in the audit report on the consolidated financial statements remains.

The Company will continue to take the necessary steps to resolve this situation as soon as possible.

• **Final Remarks**

The Company notes that:

- The qualification refers exclusively to a specific financial asset and does not affect the business as a whole or the Group’s operations.
- It has no impact on the individual financial statements of LABIANA HEALTH, S.A., whose audit report was issued with an unqualified opinion.
- It does not compromise the Company’s ability to continue operating or its overall financial position.

In accordance with the provisions of BME Growth Circular 3/2020, it is noted that the information disclosed has been prepared under the sole responsibility of the Company and its directors.

---

Mr. Manuel Ramos Ortega  
Chairman and Chief Executive  
Officer of LABIANA HEALTH, S.A.